TScan Therapeutics, Inc. (TCRX) stock
TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15−0.00 (-1.72%)
Close on Nov 18, 2026Market cap $10.06MP/E –Yield –
TScan Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
TScan Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$116.28M. For fiscal 2025 it was -$135.32M. The highest annual figure on record is -$3.02M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$135.32M | – |
| FY2024 | Dec 31, 2024 | -$110.82M | – |
| FY2023 | Dec 31, 2023 | -$61.36M | – |
| FY2022 | Dec 31, 2022 | -$66.50M | – |
| FY2021 | Dec 31, 2021 | -$48.68M | – |
| FY2020 | Dec 31, 2020 | -$3.02M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$27.54M | – |
| Q1 FY2026 | Mar 31, 2026 | -$24.28M | – |
| Q4 FY2025 | Dec 31, 2025 | -$32.00M | – |
| Q3 FY2025 | Sep 30, 2025 | -$32.46M | – |
| Q2 FY2025 | Jun 30, 2025 | -$33.27M | – |
| Q1 FY2025 | Mar 31, 2025 | -$37.59M | – |
| Q4 FY2024 | Dec 31, 2024 | -$27.41M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.92M | -448.2% |
| Q2 FY2024 | Jun 30, 2024 | -$26.23M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.27M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.77M | – |
| Q3 FY2023 | Sep 30, 2023 | $8.02M | – |
| Q2 FY2023 | Jun 30, 2023 | -$22.02M | – |
| Q1 FY2023 | Mar 31, 2023 | -$23.59M | – |
| Q4 FY2022 | Dec 31, 2022 | -$16.01M | – |
| Q3 FY2022 | Sep 30, 2022 | -$17.00M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.37M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.12M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.38M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.64M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.70M | – |
| Q1 FY2021 | Mar 31, 2021 | -$9.96M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.35M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.79M | – |
See a number that looks wrong?